The team has developed synthetic 'DNA switches' that can control genes in certain cells. It's believed the technology could ...
The significance of this is that it brings about the ability to obtain FDA approval for this AAV gene therapy without the need to run a phase 3 study. Even better, it has another positive worth ...
Researchers have used artificial intelligence to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types. Their new approach opens the ...
Researchers used AI to design thousands of new DNA switches that can precisely control the expression of a gene in different cell types.
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).
Months after disclosing significant layoffs across its North Carolina operations, Pfizer (NYSE: PFE) plans to eliminate more ...
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...
RNA editing has picked up steam in recent years as a potentially safer alternative to gene editing to treat genetic diseases.
Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback